

FRIULCHEM FINALISES AN AGREEMENT WITH A NEW ZEALAND COMPANY IN THE VETERINARY INDUSTRY

THE PARTNERSHIP INCLUDES THE EXCLUSIVE SUPPLY OF COMPLEMENTARY FEEDS FOR THE AUSTRALIAN AND NEW ZEALAND MARKETS WITH A FORMULATION DEVELOPED BY FRIULCHEM USING PATENTED FC-CUBES® TECHNOLOGY

Milan, 4 May 2023 - **Friulchem S.p.A.** Friulchem (AIM: FCM) is an innovative SME and one of the main Italian operators active internationally in R&D as a Contract Development and Manufacturing Organization (CDMO). On behalf of third parties, it manufactures semi-finished and finished products containing active pharmaceutical ingredients and feed supplements. Specialising in drug delivery for the veterinary industry, Friulchem is delighted to **announce that it has entered into a collaboration agreement with a company operating in the sector for the exclusive supply in Australia and New Zealand of complementary feeds with formulations developed by Friulchem based on its proprietary FC-Cubes® technology.**

The five-year agreement specifically stipulates that the New Zealand company will oversee the marketing and distribution in Australia and New Zealand of complementary feeds for cats and dogs manufactured exclusively by Friulchem in Italy.

Disma Giovanni Mazzola, CEO of Friulchem, commented: *"Friulchem's presence is growing internationally, in line with the company's strategy, confirming our determination to play an increasingly important role in European and other markets. We consider this agreement strategic, because it will allow us to expand in two strategic markets with high growth potential. Overall, 2022 was a positive year for Friulchem. We signed important agreements and continued our investments in R&D, bolstered by the quality of our business and by our unique and innovative solutions. And we do not intend to stop there. Indeed, we are prepared for further expansion and to grasp all opportunities that will present themselves on our target market, which is characterised by constant growth".*

The press release can be found at <https://friulchem.com/it/media-relations/>

Friulchem (AIM:FCM), which has been active on the market for more than two decades, is currently one of the leading Contract Development and Manufacturing Organizations (CDMOs) in Italy. It operates internationally in healthcare through research and development and, on behalf of third parties, in the production of semi-finished and finished products containing both active pharmaceutical constituents and dietary supplements. Friulchem excels in the development of drug delivery systems for the veterinary industry but is also involved in generic drug dossiers for humans. Friulchem is an innovative B2B SME that prides itself on its focus on the end customer. With manufacturing facilities in Vivaro (Pordenone) and administrative headquarters in Milan, it has strong Italian roots. The company, strongly oriented towards R&D activities, boasts established relationships with the leading multinationals in the pharmaceutical sector.

ISIN ordinary share code: IT0005378457

Friulchem S.p.A.

ir@friulchem.com

Tel: +39 02 36591450

CFO SIM S.p.A. - Euronext Growth Advisor

ecm@cfosim.com

Tel: +39 02 30343 1

CDR Communication - Investor Relations

Silvia Di Rosa silvia.dirosa@cdr-communication.it

Claudia Messina claudia.messina@cdr-communication.it

Media Relations

Marianna Tremolada marianna.tremolada@cdr-communication.it